United Therapeutics Corporation Stock News

Emerald Advisers LLC increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 189,807 shares of the biotechnology companys stock after purchasing an additional 2,347 shares during the []

Thrivent Financial for Lutherans reduced its position in United Therapeutics Co. (NASDAQ:UTHR) by 52.5% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 11,892 shares of the biotechnology companys stock after selling 13,156 shares during the period. Thrivent Financial for Lutherans holdings in United Therapeutics were worth $2,134,000 as of its most recent SEC filing. []

Wall Street analysts forecast that United Therapeutics Co. (NASDAQ:UTHR) will report earnings of $3.79 per share for the current quarter, according to Zacks. Five analysts have issued estimates for United Therapeutics earnings, with the highest EPS estimate coming in at $3.91 and the lowest estimate coming in at $3.60. United Therapeutics posted earnings of $2.19 []

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics was named by Newsweek as one of Americas Most Responsible Companies.

Symmetry Partners LLC reduced its stake in United Therapeutics Co. (NASDAQ:UTHR) by 3.2% during the third quarter, HoldingsChannel reports. The fund owned 2,807 shares of the biotechnology companys stock after selling 94 shares during the period. Symmetry Partners LLCs holdings in United Therapeutics were worth $530,000 as of its most recent SEC filing. Other hedge []

Polianta Ltd bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,300 shares of the biotechnology companys stock, valued at approximately $1,162,000. A number of other hedge funds and other institutional investors []

Related Stocks: UTHR ,

By Memorandum Opinion entered by The Honorable Richard G. Andrews in United Therapeutics Corporation v. Liquidia Technologies, Inc., Civil Action No. 20-755-RGA (D.Del. November 18, 2021), the Court issued its claim construction of the two remaining disputed terms of U.S. Patent No. 9,604,901... By: Fox Rothschild LLP

Equities research analysts forecast that United Therapeutics Co. (NASDAQ:UTHR) will report earnings of $3.79 per share for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for United Therapeutics earnings, with estimates ranging from $3.60 to $3.91. United Therapeutics reported earnings of $2.19 per share in the same quarter last year, []

Bank of America Corp DE lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 25.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 134,109 shares of the biotechnology companys stock after selling 46,117 shares during the period. Bank of []

LPL Financial LLC raised its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,406 shares of the biotechnology companys stock after acquiring an additional 108 shares during the quarter. LPL Financial LLCs holdings []

Related Stocks: LNTH , CDNA , SRDX , SIEN , EPIX , NPCE , DICE , UTHR , FLXN , ENTA , ORGO , NRIX , MDXG , RVMD , TKNO , GLTO , PODD , DXCM ,

Related Stocks: UTHR ,

Invesco Ltd. reduced its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 10.2% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 568,135 shares of the biotechnology companys stock after selling 64,621 shares during the quarter. Invesco Ltd.s holdings in United Therapeutics were worth $101,929,000 at the end of the most recent reporting period. []

United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.